comprehensive -WSS

comprehensive

author：focus 2025-10-01 17:34:27 - browse：45138

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Fauci's latest grilling in Congress: 9 hours, behind closed doors

WSS

JPM: CVS says Medicare Advantage patients are impacting profits

J&J to buy cancer drug developer Ambrx Biopharma

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Study suggests new cause of Down syndrome: cells linked to aging

Federal weight loss drug coverage is 30 years out of date

JPM: CVS says Medicare Advantage patients are impacting profits

hotspot

comprehensive

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

How to save PrEP access — and even expand it

Videos point to link between seizures and unexplained toddler deaths

Medical leaders decry Supreme Court decision on affirmative action

JPM pitch from hospitals? Revenue streams outside of patient care

How to save PrEP access — and even expand it

Male doctors called my cancer incurable. A female doctor showed it wasn't

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Study suggests new cause of Down syndrome: cells linked to aging

leisure time

Medicare Advantage coverage denials need scrutiny, senators say

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Medicare Advantage coverage denials need scrutiny, senators say

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

J&J to buy cancer drug developer Ambrx Biopharma

3 medical device trends to watch in 2024

hotspot

leisure time

leisure time

entertainment